Literature DB >> 1655245

Allelotype of human ovarian cancer.

T Sato1, H Saito, R Morita, S Koi, J H Lee, Y Nakamura.   

Abstract

In order to determine which chromosome(s) carries a tumor suppressor gene(s) for human ovarian cancer, we examined loss of heterozygosity in 37 tumors with a set of polymorphic DNA markers which cover each autosomal chromosome arm partially. Frequent losses were observed in chromosomes 4p (42%), 6p (50%), 7p (43%), 8q (31%), 12p (38%), 12q (33%), 16p (33%), 16q (38%), 17p (46%), 17q (39%), and 19p (34%). In addition to these chromosomes, frequent losses of alleles on chromosomes 6q, 13q, and 19q were observed uniquely in serous and serous papillary cystadenocarcinomas; loss of heterozygosity was detected only rarely on these chromosomal arms in nonserous types of tumors. The average (0.12) of fractional allelic loss seen in mucinous cystadenocarcinoma, which usually has a better prognosis than other types, was much lower than that of other tumor phenotypes including serous cystadenocarcinoma (0.31) and clear cell carcinoma (0.20). These results suggested that (a) a large number of tumor suppressor genes might play a role in ovarian cancer, (b) losses of alleles in different chromosomal regions could account for differences in histopathological features and/or prognoses among patients, and (c) this kind of analysis can contribute to an improved understanding of tumor development and/or progression in human ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1655245

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  59 in total

1.  How many mutations in a cancer?

Authors:  Ian Tomlinson; Peter Sasieni; Walter Bodmer
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

2.  Allelic analysis of serous ovarian carcinoma reveals two putative tumor suppressor loci at 18q22-q23 distal to SMAD4, SMAD2, and DCC.

Authors:  H Lassus; R Salovaara; L A Aaltonen; R Butzow
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

3.  Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma.

Authors:  K Helin; K Holm; A Niebuhr; H Eiberg; N Tommerup; S Hougaard; H S Poulsen; M Spang-Thomsen; P Norgaard
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

4.  Mutation screening analysis of the retinoblastoma related gene RB2/p130 in sporadic ovarian cancer and head and neck squamous cell cancer.

Authors:  A J Alvi; R Hogg; J S Rader; M J Kuo; E R Maher; F Latif
Journal:  Mol Pathol       Date:  2002-06

5.  Monoallelic expression of the insulin-like growth factor-2 gene in ovarian cancer.

Authors:  K Yun; M Fukumoto; Y Jinno
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

6.  Genetic and epigenetic silencing of the beclin 1 gene in sporadic breast tumors.

Authors:  Zidong Li; Bo Chen; Yiqing Wu; Feng Jin; Yongjing Xia; Xiangjun Liu
Journal:  BMC Cancer       Date:  2010-03-16       Impact factor: 4.430

7.  Allelotyping of butadiene-induced lung and mammary adenocarcinomas of B6C3F1 mice: frequent losses of heterozygosity in regions homologous to human tumor-suppressor genes.

Authors:  R W Wiseman; C Cochran; W Dietrich; E S Lander; P Söderkvist
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

8.  Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas.

Authors:  D L Persons; L C Hartmann; J F Herath; T J Borell; W A Cliby; G L Keeney; R B Jenkins
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

9.  Linkage studies with 17q and 18q markers in a breast/ovarian cancer family.

Authors:  B J Milner; L A Allan; K F Kelly; D Cruickshank; M Hall; A Johnston; H Kitchener; D Parkin; N Haites
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

10.  pRb2/p130 protein expression and RBL2 mutation analysis in Burkitt lymphoma from Uganda.

Authors:  Sam Kalungi; Solrun J Steine; Henry Wabinga; Leif Bostad; Anders Molven
Journal:  BMC Clin Pathol       Date:  2009-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.